S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:NERV

Minerva Neurosciences - NERV Stock Forecast, Price & News

$9.23
-0.29 (-3.05%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.09
$10.28
50-Day Range
$2.53
$13.17
52-Week Range
$2.51
$15.27
Volume
625,946 shs
Average Volume
912,135 shs
Market Capitalization
$49.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
160.0% Upside
$24.00 Price Target
Short Interest
Healthy
23.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.63mentions of Minerva Neurosciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.74) to ($5.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

500th out of 1,095 stocks

Pharmaceutical Preparations Industry

233rd out of 547 stocks

NERV stock logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Stock News Headlines

Minerva Neurosciences, Inc. (NERV)
See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings
8/09/2022
Today
10/02/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+160.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-49,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.18 million
Book Value
$1.49 per share

Miscellaneous

Free Float
5,046,000
Market Cap
$49.29 million
Optionable
Optionable
Beta
-0.21

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 61)
    Exec. Chairman & CEO
    Comp: $1.19M
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 61)
    FCMA, M.B.A., MBA, Pres
    Comp: $880.44k
  • Mr. Frederick W. Ahlholm CPA (Age 56)
    CPA, Sr. VP, CFO & Sec.
    Comp: $610.68k
  • Dr. Michael Davidson M.D. (Age 72)
    Chief Medical Officer
    Comp: $657.47k
  • Mr. Joseph Reilly (Age 47)
    Sr. VP & COO
  • Mr. William B. Boni (Age 70)
    VP of Investor Relations & Corp. Communications
  • Dr. Ramana Kuchibhatla Ph.D.
    Sr. VP and Head of R&D













NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NERV shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2022?

1 Wall Street research analysts have issued 1 year price targets for Minerva Neurosciences' stock. Their NERV share price forecasts range from $24.00 to $24.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 160.0% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2022?

Minerva Neurosciences' stock was trading at $6.4080 at the start of the year. Since then, NERV stock has increased by 44.0% and is now trading at $9.23.
View the best growth stocks for 2022 here
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping the consensus estimate of ($1.84) by $0.21.

When did Minerva Neurosciences' stock split?

Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $9.23.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $49.29 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.23) on an earnings per share basis.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.